ACADIA Pharmaceuticals Inc (ACAD)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	875,956	851,307	816,840	750,883	684,798	605,725	537,226	511,346	507,069	501,189	497,541	475,660	465,004	452,513	443,359	437,973	421,205	398,491	372,612	346,193
Revenue (ttm)	US$ in thousands	957,797	929,236	890,534	813,806	726,437	631,886	550,901	520,229	517,235	511,503	512,401	493,059	484,145	474,394	463,359	458,241	441,755	419,074	393,083	366,185
Gross profit margin		91.46%	91.61%	91.72%	92.27%	94.27%	95.86%	97.52%	98.29%	98.03%	97.98%	97.10%	96.47%	96.05%	95.39%	95.68%	95.58%	95.35%	95.09%	94.79%	94.54%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $875,956K ÷ $957,797K
= 91.46%

ACADIA Pharmaceuticals Inc has shown a generally favorable trend in its gross profit margin over the past few years, steadily increasing from 94.54% as of March 31, 2020, to a peak of 98.29% as of March 31, 2023. This indicates that the company has been effectively managing its production costs and generating more revenue per dollar spent on production.

However, there was a slight dip in the gross profit margin in the subsequent periods, dropping to 91.46% as of December 31, 2024. This decline suggests that the company may have experienced challenges in maintaining its cost efficiency and pricing strategies during that period.

Overall, the gross profit margin performance of ACADIA Pharmaceuticals Inc demonstrates strong operational efficiency and profitability, with periodic fluctuations that may require further analysis to understand the underlying factors influencing the company's cost structure and pricing dynamics.